The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.319
Bid: 0.315
Ask: 0.319
Change: -0.011 (-3.35%)
Spread: 0.004 (1.27%)
Open: 0.325
High: 0.325
Low: 0.318
Prev. Close: 0.328
IDHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IDC termination; negotiations ongoing

6 Sep 2022 09:30

RNS Number : 3380Y
Integrated Diagnostics Holdings PLC
06 September 2022
 

SPA for IDH's acquisition of a stake in IDC expires; negotiations to continue

 

6 September 2022

(Cairo and London) In relation to the share purchase agreement (the "SPA") signed on 20 December 2021 by IDH (or "the Company") for the acquisition of a 50% stake in Islamabad Diagnostic Center ("IDC"), IDH has notified Evercare IGA Holdings Limited (the "Seller") of its decision to terminate the SPA on 29 August 2022. Termination has become inevitable as the Long-stop Date (which had already been extended for a period of three months) has occurred without the satisfaction of all conditions precedent ("CPs"). However, negotiations with the Seller are ongoing, with Pakistan's evolving economic challenges and geopolitical situation to be important considerations in the completion of the negotiations. In case the Company were to reach an agreement with the Seller, an amended SPA will be signed and a new Long-stop Date set.

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 520 branches as of 31 March 2022, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at idhcorp.com.

 

Contact

Nancy Fahmy

Investor Relations Director

M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com

 

Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "aims", "anticipates", "assumes", "believes", "could", "estimates", "expects", "forecasts", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would" or, in each case their negatives or other similar expressions, which are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding business and management, future growth or profitability and general economic and regulatory conditions and other matters affecting the Group.

 

Forward-looking statements reflect the current views of the Group's management ("Management") on future events, which are based on the assumptions of the Management and involve known and unknown risks, uncertainties and other factors that may cause the Group's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause the Group's actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements.

 

The Group's business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate or prediction to differ materially from those expressed or implied by the forward-looking statements contained in this communication. The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Group does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUACBUPPGQA
Date   Source Headline
5th Aug 20223:27 pmRNSDirector/PDMR Shareholding
4th Aug 20224:09 pmRNSDirector/PDMR Shareholding
3rd Aug 20226:01 pmRNSDirector/PDMR Shareholding
3rd Aug 20224:16 pmRNSDirector/PDMR Shareholding
2nd Aug 202210:43 amRNSDirector/PDMR Shareholding
27th Jul 20229:59 amRNSFinal Dividend Distribution
8th Jun 20228:45 amRNS1st Quarter Results
8th Jun 20227:00 amRNSResult of AGM
1st Jun 20225:39 pmRNSNotice of Results
23rd May 20224:35 pmRNSPrice Monitoring Extension
12th May 20225:37 pmRNSAnnual Financial Report & Notice of AGM
21st Apr 20229:46 amRNSPreliminary Results
31st Mar 202210:04 amRNSIFC and IFC MENA Fund acquire 5% stake in IDH
29th Mar 20228:30 amRNSIDH launches fifth Al-Borg Scan Branch
1st Mar 20222:00 pmRNSDirectorate Change
20th Dec 202110:26 amRNSReplacement: IDH 50% Acquisition of IDC
20th Dec 20218:00 amRNSIDH Acquisition of Islamabad Diagnostic Centre
16th Nov 20217:00 amRNS3rd Quarter Results
12th Nov 202112:03 pmRNSNotice of Results
28th Oct 20214:34 pmRNSNotice of Arbitration
4th Oct 202111:48 amRNSIDH launches third Al-Borg Scan branch
24th Sep 202112:50 pmRNSIDH 1H 2021 Standalone Financial Statements
2nd Sep 20217:00 amRNSHalf-year Report
18th Aug 202110:04 amRNSBiolab to operate testing stations in QAIA
9th Jul 20214:16 pmRNSFinal dividend clarification
30th Jun 202112:21 pmRNSResult of AGM
17th Jun 202110:02 amRNSFinal Dividend Resolution – Date Amendments
7th Jun 20215:24 pmRNSAnnual Financial Report & Notice of AGM
7th Jun 20217:00 amRNSChange of Auditor
2nd Jun 20217:00 amRNS1st Quarter Results
27th May 20215:07 pmRNSShare Transfer Mechanism and Documents
25th May 20217:00 amRNSIDH partners with IFC on USD 45m debt financing
20th May 202111:58 amRNSIDH debuts trading on EGX
19th May 20217:00 amRNSFinal Results
6th May 20216:02 pmRNSFRA dual listing approval
5th May 202110:21 amRNSIDH EGX Dual Listing Approval
22nd Mar 202112:31 pmRNSDual Listing - FRA registration approval
18th Feb 202112:25 pmRNSTrading update for the year ended 31 December 2020
17th Feb 20214:41 pmRNSSecond Price Monitoring Extn
17th Feb 20214:36 pmRNSPrice Monitoring Extension
15th Jan 20214:36 pmRNSPrice Monitoring Extension
31st Dec 202012:40 pmRNSSecond Price Monitoring Extn
31st Dec 202012:35 pmRNSPrice Monitoring Extension
29th Dec 20204:36 pmRNSPrice Monitoring Extension
23rd Dec 20201:35 pmRNSResults of EGM and Subdivision of Share Capital
4th Dec 20207:00 amRNSNotice of Extraordinary General Meeting
27th Nov 20204:36 pmRNSPrice Monitoring Extension
20th Nov 20204:40 pmRNSSecond Price Monitoring Extn
20th Nov 20204:35 pmRNSPrice Monitoring Extension
19th Nov 20207:00 amRNS3rd Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.